<DOC>
	<DOC>NCT00448214</DOC>
	<brief_summary>To evaluate the safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation (NVAF)and to obtain information on pharmacokinetics and pharmacodynamics (anti-thrombotic potential) in the target population</brief_summary>
	<brief_title>Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Darexaban</mesh_term>
	<mesh_term>Factor Xa Inhibitors</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Subjects are eligible for the study if all of the following apply: Subject has paroxysmal permanent or persistent NVAF Subject has INR of 2.0 or below and an aPTT â‰¤ 1.5 times the upper limit of normal at the baseline visit. Legal minimum age requirement (countryspecific). Written informed consent has been obtained. History of heart valve disorders History of rheumatic fever. History of stroke and/or systemic embolism (including TIA). History of Acute Coronary Syndrome (ACS). Indication for warfarin other than NVAF. Known hemorrhagic disorder and/or coagulation disorder. Active bleeding or any condition associated with increased risk of bleeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Factor Xa inhibitor</keyword>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Stroke</keyword>
	<keyword>Ischemic attack</keyword>
	<keyword>thromboembolism</keyword>
	<keyword>Prevention and control</keyword>
</DOC>